Orchard Therapeutics Receives FDA Approval of Lenmeldy(TM) (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.

Stock Information for Chico's FAS Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Chico's FAS Inc.

Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy(TM) (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.